Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced participation in two upcoming investor conferences. The 29th Annual Credit Suisse Virtual Healthcare Conference is on November 9 at 5 p.m. Eastern Time, and the Barclays Gene Editing & Gene Therapy Summit is scheduled for November 16 at 10:45 a.m. Eastern Time. Both presentations will be webcast live and later available on their website under the Investors and Media section. Sangamo focuses on advancing genomic medicines through gene therapy and genome editing.
- None.
- None.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
29th Annual Credit Suisse Virtual Healthcare Conference
Presentation Date: Monday, November 9th at 5 p.m. Eastern Time
-
Barclays Gene Editing & Gene Therapy Summit
Presentation Date: Monday, November 16th at 10:45 a.m. Eastern Time
Presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo website after the event.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.
